IDYA
IDEAYA Biosciences, Inc.NASDAQHealthcare$32.74+0.80%ClosedMarket Cap: $2.88B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.80
P/S
12.98
EV/EBITDA
-23.11
DCF Value
$-134.03
FCF Yield
-2.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.9%
Operating Margin
-72.8%
Net Margin
-52.0%
ROE
-11.1%
ROA
-10.2%
ROIC
-15.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $10.9M | 89.0% | $-94.6M | $-83.3M | $-0.94 | — |
| FY 2025 | $218.7M | 97.9% | $-159.3M | $-113.7M | $-1.28 | — |
| Q3 2025 | $207.8M | 99.5% | $108.5M | $119.2M | $1.33 | — |
| Q2 2025 | $0.00 | -Infinity% | $-88.8M | $-77.5M | $-0.88 | — |
| Q1 2025 | $0.00 | -Infinity% | $-84.4M | $-72.2M | $-0.82 | — |
| Q4 2024 | $7.0M | 90.8% | $-144.1M | $-130.3M | $-1.49 | — |
| FY 2024 | $7.0M | 45.2% | $-327.0M | $-274.5M | $-3.36 | — |
| Q3 2024 | $0.00 | -Infinity% | $-66.9M | $-51.8M | $-0.60 | — |
| Q2 2024 | $0.00 | -Infinity% | $-64.9M | $-52.8M | $-0.68 | — |
| Q1 2024 | $0.00 | -Infinity% | $-51.0M | $-39.6M | $-0.53 | — |
| Q4 2023 | $3.9M | 73.9% | $-41.9M | $-34.0M | $-0.52 | — |
| FY 2023 | $23.4M | 82.9% | $-134.4M | $-113.0M | $-1.96 | — |